Abstract
Objective. To record diagnostic and treatment approaches to gouty arthritis among US rheumatologists. Methods. Questionnaires were faxed to 2500 US rheumatologists. Results. Responses were received from 518 rheumatologists. Respondents reported performing crystal analysis 80% of the time for new suspected gout; 64% use combination therapy for acute gout; non-steroidal antiinflammatory drugs alone are used in only 27%. Urate-lowering drugs (ULD) are given to most patients. ULD treatment is given occasionally to patients with asymptomatic hyperuricemia (4%) but most frequently to patients after 2 (59%) or 3 (34%) attacks. ULD are given with the aim of achieving a serum urate (SU) level of 6 mg/dl. Conclusion. Combination antiinflammatory agents are used frequently for acute gout despite absence of evidence in the literature to support this practice. There seems to be consensus regarding the necessity of lowering SU to < 6 mg/dl. Approaches vary widely, supporting the need for longterm prospective, placebo controlled studies to provide more evidence-based guidance.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2050-2052 |
| Number of pages | 3 |
| Journal | Journal of Rheumatology |
| Volume | 33 |
| Issue number | 10 |
| State | Published - Oct 1 2006 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Rheumatology
- Immunology and Allergy
- Immunology
Keywords
- Gout
- Survey
- Treatment
Cite this
}
A survey of current evaluation and treatment of gout. / Schlesinger, Naomi; Moore, Dirk; Sun, Jennifer D.; Schumacher, H. Ralph.
In: Journal of Rheumatology, Vol. 33, No. 10, 01.10.2006, p. 2050-2052.Research output: Contribution to journal › Review article
TY - JOUR
T1 - A survey of current evaluation and treatment of gout
AU - Schlesinger, Naomi
AU - Moore, Dirk
AU - Sun, Jennifer D.
AU - Schumacher, H. Ralph
PY - 2006/10/1
Y1 - 2006/10/1
N2 - Objective. To record diagnostic and treatment approaches to gouty arthritis among US rheumatologists. Methods. Questionnaires were faxed to 2500 US rheumatologists. Results. Responses were received from 518 rheumatologists. Respondents reported performing crystal analysis 80% of the time for new suspected gout; 64% use combination therapy for acute gout; non-steroidal antiinflammatory drugs alone are used in only 27%. Urate-lowering drugs (ULD) are given to most patients. ULD treatment is given occasionally to patients with asymptomatic hyperuricemia (4%) but most frequently to patients after 2 (59%) or 3 (34%) attacks. ULD are given with the aim of achieving a serum urate (SU) level of 6 mg/dl. Conclusion. Combination antiinflammatory agents are used frequently for acute gout despite absence of evidence in the literature to support this practice. There seems to be consensus regarding the necessity of lowering SU to < 6 mg/dl. Approaches vary widely, supporting the need for longterm prospective, placebo controlled studies to provide more evidence-based guidance.
AB - Objective. To record diagnostic and treatment approaches to gouty arthritis among US rheumatologists. Methods. Questionnaires were faxed to 2500 US rheumatologists. Results. Responses were received from 518 rheumatologists. Respondents reported performing crystal analysis 80% of the time for new suspected gout; 64% use combination therapy for acute gout; non-steroidal antiinflammatory drugs alone are used in only 27%. Urate-lowering drugs (ULD) are given to most patients. ULD treatment is given occasionally to patients with asymptomatic hyperuricemia (4%) but most frequently to patients after 2 (59%) or 3 (34%) attacks. ULD are given with the aim of achieving a serum urate (SU) level of 6 mg/dl. Conclusion. Combination antiinflammatory agents are used frequently for acute gout despite absence of evidence in the literature to support this practice. There seems to be consensus regarding the necessity of lowering SU to < 6 mg/dl. Approaches vary widely, supporting the need for longterm prospective, placebo controlled studies to provide more evidence-based guidance.
KW - Gout
KW - Survey
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=33750034285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750034285&partnerID=8YFLogxK
M3 - Review article
C2 - 17014020
AN - SCOPUS:33750034285
VL - 33
SP - 2050
EP - 2052
JO - Journal of Rheumatology
JF - Journal of Rheumatology
SN - 0315-162X
IS - 10
ER -